Literature DB >> 2454134

Antibodies to the N-terminus of calpactin II (p35) affect Ca2+ binding and phosphorylation by the epidermal growth factor receptor in vitro.

J Glenney1, L Zokas.   

Abstract

Calpactins I and II are related 39-kilodalton (kDa) proteins that interact with phospholipids and actin in a calcium-dependent manner and are substrates of tyrosine protein kinases. They contain a short amino-terminal tail attached to a 36-kDa core domain. Monoclonal antibodies (Mabs) were raised to bovine calpactin II and used as site-specific probes of its structure and function. All of the antibodies reacted with native calpactin II and gave rise to a single band of 39 kDa among total cell protein displayed on Western blots. Most of the antibodies (9/14) reacted with determinants on the tail as shown by Western blots and competition with a synthetic tail peptide. Four antibodies reacted with determinants on the core and a 10-kDa tryptic fragment. Antibody-calpactin II complexes were tested for their ability to interact with lipid, actin, and Ca2+ and to serve as substrates of the epidermal growth factor (EGF) receptor tyrosine protein kinase. Whereas none of the antibodies had a detectable effect on actin binding, two anticore antibodies reduced calpactin's affinity for phospholipid. Ca2+-binding sites are known to reside within the core region, yet most antitail antibodies markedly increased the affinity of calpactin II for Ca2+, with four Ca2+-binding sites observed. Antitail antibodies either (i) abolished or (ii) greatly stimulated (10-fold) the phosphorylation of calpactin II by the EGF receptor. These results suggest that the interactions between calpactin II and Ca2+, phospholipid, or the EGF receptor are more complex than previously thought and can be modulated by interactions occurring in the tail.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454134     DOI: 10.1021/bi00406a038

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  A dimeric form of lipocortin-1 in human placenta.

Authors:  R B Pepinsky; L K Sinclair; E P Chow; B O'Brine-Greco
Journal:  Biochem J       Date:  1989-10-01       Impact factor: 3.857

2.  Crystal structure of human annexin I at 2.5 A resolution.

Authors:  X Weng; H Luecke; I S Song; D S Kang; S H Kim; R Huber
Journal:  Protein Sci       Date:  1993-03       Impact factor: 6.725

3.  Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues.

Authors:  S H Ahn; H Sawada; J Y Ro; G L Nicolson
Journal:  Clin Exp Metastasis       Date:  1997-03       Impact factor: 5.150

4.  cDNA structure and expression of calpactin, a peptide involved in Ca2(+)-dependent cell aggregation in sponges.

Authors:  A Robitzki; H C Schröder; D Ugarković; M Gramzow; U Fritsche; R Batel; W E Müller
Journal:  Biochem J       Date:  1990-10-15       Impact factor: 3.857

5.  Monoclonal antibodies specific to a Ca2(+)-bound form of lipocortin I distinguish its Ca2(+)-dependent phospholipid-binding ability from its ability to inhibit phospholipase A2.

Authors:  H Hayashi; M K Owada; S Sonobe; K Domae; T Yamanouchi; T Kakunaga; Y Kitajima; H Yaoita
Journal:  Biochem J       Date:  1990-08-01       Impact factor: 3.857

6.  Calcium-dependence of synexin binding may determine aggregation and fusion of lamellar bodies.

Authors:  N Sen; A R Spitzer; A Chander
Journal:  Biochem J       Date:  1997-02-15       Impact factor: 3.857

7.  Expression of human recombinant lipocortin I in a wheat-germ cell-free system and Xenopus oocytes. Lipocortin is not secreted.

Authors:  B M Frey; F J Frey; V R Lingappa; H Trachsel
Journal:  Biochem J       Date:  1991-04-01       Impact factor: 3.857

8.  Epitope mapping of annexin I: antibodies that compete with phospholipids and calcium recognize amino acids 42-99.

Authors:  J D Ernst
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

9.  Clinical significance of annexin A1 expression in breast cancer.

Authors:  Cha Kyong Yom; Wonshik Han; Sung-Won Kim; Hee Sung Kim; Hee-Chul Shin; Ji Na Chang; Minyoung Koo; Dong-Young Noh; Byung-In Moon
Journal:  J Breast Cancer       Date:  2011-12-27       Impact factor: 3.588

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.